Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, has received the U.S. Food and Drug Administration's approval of its 10 mg/mL strength of Ketamine Hydrochloride Injection, USP, the generic equivalent of JHP Pharmaceuticals' Ketalar®CIII.

The 10 mg/mL strength joins Bioniche's current offering of Ketamine in 50 mg/mL and 100 mg/mL strengths and completes its full product line offering. Bioniche plans to launch the 10 mg/mL strength in October. "We are pleased to offer our customers a full line of Ketamine for their treatment needs," said Steve Thornton, CEO Bioniche Pharma.